CD20, a transmembrane protein expressed on the surface of B cells, plays a pivotal role in B-cell development, differentiation, and signaling. It is involved in the regulation of a crucial step in the B-cell cycle, particularly in the transition from pre-B cells to mature B cells. The precise function of CD20 remains somewhat elusive; however, it is known to act as a calcium channel, modulating intracellular calcium levels and thus influencing B cell activation, proliferation, and survival. The expression of CD20 is tightly regulated throughout the B-cell lineage, with its expression starting at the pre-B cell stage and continuing through to the mature B cell, albeit with a decrease in expression as the cell transitions to a plasma cell. This pattern of expression suggests that CD20 plays a key role in maintaining the balance between B cell activation and quiescence, ensuring a proper immune response.
The activation of CD20 and its downstream effects on B-cell physiology are mediated through complex signaling pathways. Upon engagement with specific ligands or antibodies, CD20 can transduce signals that lead to the activation of various intracellular kinase pathways, such as PI3K/Akt and MAPK, which in turn influence cell cycle progression, differentiation, and apoptosis. The mechanism of CD20 activation involves its interaction with other cell surface receptors and the cytoskeleton, facilitating the formation of signaling complexes that trigger downstream responses. Furthermore, CD20's role in regulating intracellular calcium flux is critical for the activation of transcription factors necessary for B-cell proliferation and antibody production. The precise modulation of CD20 activity is essential for the proper function of the immune system, highlighting its significance in both the initiation and regulation of immune responses. Understanding the mechanisms behind CD20 activation provides valuable insights into the intricate network of B-cell regulation and its implications in immune competency and pathology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid can upregulate CD20 expression in certain B-cell lymphomas, enhancing their sensitivity to CD20-targeted therapies. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
This immunomodulatory suggested compound can increase CD20 expression on the surface of some B-cell lymphomas, making them more susceptible to CD20-targeted therapies. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
As a DNA methyltransferase inhibitor, decitabine can alter gene expression profiles, potentially influencing CD20 expression. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
A histone deacetylase inhibitor that can increase CD20 expression in certain B-cell malignancies. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can upregulate CD20 expression in certain B-cell malignancies. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
As a proteasome inhibitor, MG132 can influence various cellular processes, potentially including CD20 expression. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Immunosuppressive suggested compound that might influence CD20 expression, though more research is needed. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | $245.00 | 9 | |
It can influence protein kinase C (PKC) activity and has been shown to upregulate CD20 expression in certain contexts. | ||||||